Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Drug Safety

Volumn 16, Issue 5, 1997, Pages 289-294

  Mizuno, Yoshikuni ^a   Kondo, Tomoyoshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; SELEGILINE;

ARTICLE; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; MORTALITY; PARKINSON DISEASE; PATIENT INFORMATION; PRIORITY JOURNAL; SIDE EFFECT; UNITED KINGDOM;

EID: 0030958295     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716050-00001     Document Type: Article

References (43)

1. Demarest K, Smith D, Azzaro A. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 1980; 215: 461-8
2. Damier P, Kastner A, Agid Y, et al. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease? Neurology 1996; 46: 1262-9
3. Levitt P, Pintar J, Breakfield X. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982; 79: 6385-9
4. Chiba K, Trevor AJ, Castagnoli Jr N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120: 574-8
5. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467-9
6. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-83
7. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29-36
8. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995; 38: 771-7
9. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995; 311: 1602-7
10. Parkinson's Disease Research Group in the United Kingdom. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three-year interim report. BMJ 1993; 307: 469-72
11. Mäki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Other studies have not shown increased mortality [letter]. BMJ 1996; 312: 702
12. Anderson KE, Girdwood AC, Wilson JA. Stopping selegiline may lead to problems for patients [letter]. BMJ 1996; 312: 702
13. Olanow CW, Goodbold JH, Koller W. Patients taking selegiline may have received more levodopa than necessary [letter]. BMJ 1996; 312: 702-3
14. MacMahon DG, Bland R. Selegiline is effective and safe in early stages [letter]. BMJ 1996; 312: 703
15. Silva MT, Watts PM, Jenner P. Parkinson's disease is rarely a primary cause of death [letter]. BMJ 1996; 312: 703
16. Yu PH, Lai CT, Boulton AA. Selegiline may be toxic in presence of increased dopamine concentrations [letter]. BMJ 1996; 312: 703-4
17. Gerlach M, Riederer P, Vogt H. 'On treatment' rather than intention to treat analysis should have been used [letter]. BMJ 1996; 312: 704
18. Jellinger KA. Causes of death need confirmation [letter]. BMJ 1996; 312: 704
19. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disorders 1992; 7: 23-31
20. Spencer JPE, Jenner A, Aruoma OJ, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994; 353: 246-50
21. Tanaka M, Sotomatsu A, Kanai H, et al. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron. Neurosci Lett 1992; 140: 42-6
22. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; Suppl. 19: 253-64
23. Diamond SG, Markham CH, Hoehn MM, et al. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8-12
24. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990; 40: 265-9
25. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61: 1470-8
26. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501-10
27. Duarte J, Almuiña JV, Sevillano MD, et al. Atrial fibrillation induced by selegiline. Parkinsonism Related Disord 1996; 2: 125-6
28. Lees AJ, Shaw KM, Kohoul LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977; 11: 791-5
29. Rinne UK, Siirtola T, Sonninen V. L-Deprenyl treatment of on-off phenomena in Parkinson's disease. J Neural Transm 1978; 43: 253-62
30. Schachter M, Marsden CD, Parkes JD. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. J Neurol Neurosurg Psychiatry 1980; 43: 1016-21
31. Brodersen P, Philbert A, Gulliksen G, et al. The effect of L-deprenyl on on-off phenomena in Parkinson's disease. Acta Neurol Scand 1985; 71: 494-7
32. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol 1988; 11: 45-55
33. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology 1989; 39: 1109-11
34. Cedarbaum JM, Silvestri M, Clark M, et al. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. Clin Neuropharmacol 1990; 13: 29-35
35. Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord 1993; 1; S41-4
36. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 45: 519-22
37. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegiline in de novo parkinsonian patients. Mov Disord 1993; 8: S36-40
38. Teräväinen H. Selegiline in Parkinson's disease. Acta Neurol Scand 1990; 81: 333-6
39. Brannan T, Yahr M. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995; 37: 95-8
40. Rinne UK. Combination of a dopamine agonist, MAO-B inhibiitor and levodopa: a new strategy in the treatment of early Parkinson's disease. Acta Neurol Scand 1989; 126: 165-9
41. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541-4
42. Elizan TS, Yahr MD, Moros DA, et al. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease: experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol 1989; 48: 1280-3
43. Yahr MD. [editorial]. Parkinsonism Related Disord 1996; 2: 123-4